首页> 美国卫生研究院文献>Acta Pharmaceutica Sinica. B >Targeting slug-mediated non-canonical activation of c-Met to overcome chemo-resistance in metastatic ovarian cancer cells
【2h】

Targeting slug-mediated non-canonical activation of c-Met to overcome chemo-resistance in metastatic ovarian cancer cells

机译:靶向介导的c-Met非规范激活以克服转移性卵巢癌细胞的化学耐药性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Metastasis-associated drug resistance accounts for high mortality in ovarian cancer and remains to be a major barrier for effective treatment. In this study, SKOV3/T4, a metastatic subpopulation of ovarian cancer SKOV3 cells, was enriched to explore potential interventions against metastatic-associated drug resistance. Quantitative genomic and functional analyses were performed and found that slug was significantly increased in the SKOV3/T4 subpopulation and contributed to the high resistance of SKOV3/T4. Further studies showed that slug activated c-Met in a ligand-independent manner due to elevated levels of fibronectin and provoked integrin α V function, which was confirmed by the significant correlation of slug and p-Met levels in 121 ovarian cancer patient samples. Intriguingly, c-Met inhibitor(s) exhibited greatly enhanced anti-cancer effects in slug-positive ovarian cancer models both in vitro and in vivo. Additionally, IHC analyses revealed that slug levels were highly correlated with reduced survival of ovarian cancer patients. Taken together, this study not only uncovers the critical roles of slug in drug resistance in ovarian cancer but also highlights a promising therapeutic strategy by targeting the noncanonical activation of c-Met in slug-positive ovarian cancer patients with poor prognosis.
机译:与转移相关的耐药性导致卵巢癌的高死亡率,并且仍然是有效治疗的主要障碍。在这项研究中,SKOV3 / T4是卵巢癌SKOV3细胞的转移亚群,其丰富的成分可用于探索针对与转移相关的耐药性的潜在干预措施。进行了定量的基因组和功能分析,发现在SKOV3 / T4亚群中显着增加,并且有助于SKOV3 / T4的高抗性。进一步的研究表明,由于纤连蛋白水平升高和激发的整联蛋白αV功能,以不依赖配体的方式激活c-Met,这一点已被121个卵巢癌患者样品中的and和p-Met水平显着相关所证实。有趣的是,无论在体内还是体外,c-Met抑制剂在阳性卵巢癌模型中均表现出极大的抗癌作用。此外,IHC分析显示,水平与卵巢癌患者生存率降低高度相关。综上所述,这项研究不仅揭示了在卵巢癌耐药中的关键作用,而且通过针对预后不良的阳性卵巢癌患者中c-Met的非规范激活,突出了一种有前途的治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号